1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. USA ANTIBODY DRUG CONJUGATES MARKET BY TARGET
5.1. Introduction
5.2. CD 30
5.3. CD 22
5.4. HER 2
6. USA ANTIBODY DRUG CONJUGATES MARKET BY INDICATION
6.1. Introduction
6.2. Hematologic Malignancies
6.3. Non- Hematologic Malignancies
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Market Share Analysis
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Competitive Dashboard
8. COMPANY PROFILES
8.1. Takeda Pharmaceutical Company Limited
8.2. F. Hoffmann-La Roche Ltd.
8.3. Pfizer Inc.
8.4. Astellas Pharma Inc.
8.5. Seattle Genetics, Inc.
9. APPENDIX
9.1. Currency
9.2. Assumptions
9.3. Base and Forecast Years Timeline
9.4. Key benefits for the stakeholders
9.5. Research Methodology
9.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES